1区 · 医学
Article
作者: Albuquerque, Marco ; Yu, Stephen ; Assouline, Sarit E. ; Alamouti, Sepideh ; Alcaide, Miguel ; Camglioglu, Errol ; Oros, Kathleen Klein ; Kezouh, Abbas ; Morin, Ryan D. ; Froment, Remi ; MacDonald, David ; Tosikyan, Axel ; Chong, Lauren ; Fornika, Daniel ; Kukreti, Vishal ; Greenwood, Celia M. T. ; Christodoulopoulos, Rosa ; Mann, Koren K. ; Johnson, Nathalie ; Rousseau, Caroline ; Nielsen, Torsten Holm ; Petrogiannis-Haliotis, Tina ; Crump, Michael ; Sharma, Ayushi
Key Points:Panobinostat induces responses in 28% of patients with relapsed and refractory DLBCL that are typically durable off therapy. MEF2B mutations predicted for response whereas early increase in ctDNA abundance was a strong predictor of subsequent treatment failure.